Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oocyte mitochondria are subcellular organelles present in high numbers (100,000-400,000 per mature oocyte) that serve as the primary energy producers for oocyte maturation, fertilization, and early embryonic development. These organelles accumulate substantial mitochondrial DNA content during oocyte growth and are maternally inherited by the developing embryo. Mitochondrial ATP production is critical because glycolysis is suppressed during oocyte maturation and early preimplantation development, making oocytes uniquely dependent on oxidative phosphorylation. Mitochondrial dysfunction, characterized by impaired ATP synthesis and increased reactive oxygen species production, is associated with decreased oocyte quality, chromosomal segregation errors, and reduced fertility. While oocyte mitochondria are not conventional drug targets, therapeutic strategies have been proposed to enhance mitochondrial function—including antioxidant treatments and modulation of mitochondrial dynamics proteins—to improve fertility outcomes.
Not applicable (this is not a targetable molecular entity)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oocyte mitochondria (None standardized).